Understanding patient views on fatty liver disease study
Part of Digestive system, Hormones & metabolism clinical trials.
This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with MASH (a type of fatty liver disease with inflammation) and liver scarring (stage F2–F4).
- You are between 18 and 75 years old.
- Your body mass index (BMI) is 27 or higher.
- You are already part of the MASH-Cardiovascular Programme at Hospital de Sant Pau.
- You agree to talk with researchers in an interview about your experiences.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This study aims to better classify a common type of fatty liver disease (called MAFLD) using liver biopsy samples. It may help researchers understand different subtypes of the disease and could lead to more personalized care.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Hear when a new Metabolic Dysfunction Associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.